CN102657333B - 降压护心复合营养剂及其制备方法 - Google Patents
降压护心复合营养剂及其制备方法 Download PDFInfo
- Publication number
- CN102657333B CN102657333B CN2012101459307A CN201210145930A CN102657333B CN 102657333 B CN102657333 B CN 102657333B CN 2012101459307 A CN2012101459307 A CN 2012101459307A CN 201210145930 A CN201210145930 A CN 201210145930A CN 102657333 B CN102657333 B CN 102657333B
- Authority
- CN
- China
- Prior art keywords
- astragalus
- parts
- burdock
- heart
- selenium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000015097 nutrients Nutrition 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title claims description 5
- 230000036772 blood pressure Effects 0.000 title abstract description 13
- 239000002131 composite material Substances 0.000 title 1
- 241001061264 Astragalus Species 0.000 claims abstract description 47
- 235000006533 astragalus Nutrition 0.000 claims abstract description 47
- 210000004233 talus Anatomy 0.000 claims abstract description 47
- 235000003130 Arctium lappa Nutrition 0.000 claims abstract description 31
- 235000008078 Arctium minus Nutrition 0.000 claims abstract description 31
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 25
- 239000011669 selenium Substances 0.000 claims abstract description 25
- 244000017020 Ipomoea batatas Species 0.000 claims abstract description 24
- 235000002678 Ipomoea batatas Nutrition 0.000 claims abstract description 24
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 241000208843 Arctium Species 0.000 claims description 30
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 3
- 238000010009 beating Methods 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 229920002472 Starch Polymers 0.000 abstract description 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
- 235000019698 starch Nutrition 0.000 abstract description 2
- 239000008107 starch Substances 0.000 abstract description 2
- 240000005528 Arctium lappa Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 26
- 230000006870 function Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- 241000209140 Triticum Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 235000021307 Triticum Nutrition 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 235000010208 anthocyanin Nutrition 0.000 description 7
- 229930002877 anthocyanin Natural products 0.000 description 7
- 239000004410 anthocyanin Substances 0.000 description 7
- 150000004636 anthocyanins Chemical class 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000013311 vegetables Nutrition 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- -1 bitters Chemical class 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 235000019714 Triticale Nutrition 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000002019 anti-mutation Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002366 mineral element Substances 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 206010047470 viral myocarditis Diseases 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 241000228158 x Triticosecale Species 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical class O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002517 constrictor effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000005118 dietary health Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical class C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 210000001363 mesenteric artery superior Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 210000001883 posterior pituitary gland Anatomy 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种降压护心复合营养剂,主要由下列原料制备而成,均为重量份:富硒黑麦芽50-70;牛蒡30-40;紫薯10-20;黄芪10-15。本发明最大程度地保存了产品中的各种有效成分;所得本品因含有大量淀粉,因此无需单独添加赋形剂。
Description
技术领域
本发明属于保健品行业领域,具体是涉及一种降压护心复合营养剂及其制备方法。
背景技术
由于人们饮食习惯的改变(现在摄入蛋白质多,蔬菜少),以及蔬菜加工方式等原因,导致食物中的维生素遭到破坏,维生素以及矿物质、抗氧化物质等功能性物质的日摄入量满足不了正常代谢需求。随着经济的发展和生活节奏的加快,现代人由于工作压力、事业压力、经济压力、社会压力、婚姻压力、家庭压力等,久而久之,会出现焦虑不安、抑郁症、精神障碍等心理问题和疾病,从生理角度讲,长期精神高度紧张也会使内分泌功能失调、人体免疫力下降、身体产生过多的活性氧自由基而导致衰老加快乃至导致各种生理疾病的产生。
因此,从饮食以外补充维生素、矿物质,以及抗氧化物质等一直以来被发达国家所推崇。随着生活水平的提高和自我保健意识的逐步增强,国内对营养保健品的需求也逐年增多,相应催生了保健品行业的发展。
黄芪,性味:甘,微温。归经:归肺、脾、肝、肾经。黄芪含有蔗糖、葡萄糖醛酸、黄芪多糖A、B、C、D,黏液质,多种氨基酸、苦味素、黄芪皂苷、甜菜碱、胆碱、叶酸(65微克/100克干根)、黄烷化合物及含有硒、硅、锌、钴、铜、钼等多种微量元素。黄芪有益气固表、敛汗固脱、托疮生肌、利水消肿之功效。用于治疗气虚乏力,中气下陷,久泻脱肛,便血崩漏,表虚自汗,痈疽难溃,久溃不敛,血虚萎黄,内热消渴,慢性肾炎,蛋白尿,糖尿病等。炙黄芪益气补中,生用固表托疮。
现代医学证明,黄芪具有如下功效:1、对肝的作用:小鼠灌胃黄芪水煎液能明显促进3H-亮氨酸掺入小鼠血清和肝脏蛋白质的速率,而对蛋白质含量无影响,即可以显著促进血清和肝脏蛋白质的更新。可增加脾脏蛋白质合成,并使脾脏细胞增生,胞浆内含大量粗面内质网。黄芪对糖代谢呈双向调节作用,能显著降低葡萄糖负荷后小鼠的血糖水平,对抗肾上腺素所致的血糖升高,又能对抗苯乙双胍所致的小鼠血糖降低。黄芪对正常血糖无明显影响。2、保肝:正常小鼠灌胃黄芪水煎液可使肝糖原增加。黄芪对四氯化碳造成肝脏损害引起的血清总蛋白和白蛋白降低有回升作用,并能预防四氯化碳所致的肝糖原减少。黄芪可增加3H-亮氨酸掺入肝脏蛋白质促进其更新。慢性乙型肝炎病人存在细胞免疫功能紊乱,T细胞亚群中CD8升高,CD4/CD8比值降低,黄芪注射液可使病人CD8下降,CD4/CD8升高,恢复正常免疫功能,提高清除病毒或抑制病毒扩散的能力。3、抗疲劳:黄芪能增强大鼠和小鼠的肌力。大鼠灌胃黄芪水煎液6日或14日,能增强大鼠游泳耐疲劳的作用,并使游泳应激大鼠血浆皮质醇含量明显增加,超过空白应激组和正常对照组的水平。黄芪可使游泳应激大鼠肾上腺重量增加,肾上腺皮质增厚,束状带细胞体积增大、胞浆丰富。表明黄芪增强大鼠抗应激能力是通过增强肾上腺皮质功能来实现的。4、减缓自然衰老:黄芪能延长家蚕和果蝇的平均寿命,减缓人胎肺二倍体细胞体外培养的自然衰老过程,使细胞寿命延长达98代,对照组仅为61-66代,使寿命延长l/3。对小鼠肾细胞培养也有保护作用。黄芪并有抗氧化作用,可降低动物血清中过氧化脂质和肝脏脂褐素含量。过氧化氢损伤中国仓鼠肺细胞(V79)引起SOD活性降低,黄芪总黄酮有回升SOD活性的作用,可减少脂质过氧化物对生物膜的损害。5、调节血压与保护心脏:黄芪具有强心作用,使心脏收缩振幅增大,输出量增加,对中毒或疲劳衰竭心脏的作用更为明显。黄芪对缺糖缺氧条件下培养大鼠心肌细胞所致的乳酸脱氢酶及细病变有保护作用。在加有黄芪培养的心肌细胞内,细胞质中的线粒体和糖原颗粒丰富,而糖原颗粒是细胞的能量来源,因此,黄芪可因加强心肌细胞的能量代谢而加强其功能。黄芪多糖可对抗垂体后叶索引起的急性心肌缺血,对抗氯化钡诱发的大鼠心律失常和氯仿诱发的小鼠心室纤颤。病毒性心肌炎病人的红细胞免疫功能低下,机体清除免疫复合物的能力降低,导致病毒复制,加重炎症损伤。黄芪对病毒性心肌炎病人治疗3个月后,使NK细胞活性明显提高,使可溶性白细胞介素-2受体水平明显降低,并增强心肌细胞产生干扰素及促诱生干扰素作用。黄芪对多种动物均有降压作用。自发性高血压大鼠灌胃黄芪水煎液可使血压的上升幅度有所控制。黄芪的降压成分为γ-氨基丁酸和黄芪皂苷甲。当动物血压降至休克水平时,黄芪又可使血压稍上升且保持稳定,对血压具有一定的双向调节作用。黄芪能明显降低麻醉犬的脑血管、外周血管、冠状动脉、肠系膜上动脉的阻力,对这些部位的血管有扩张作用,但对肾血管却具有收缩作用。黄茂降压作用主要为直接扩张外周血管,降低外周阻力的结果。
小麦芽是由禾本科植物小麦的种子萌发而来,富含叶绿素、类胡萝卜素、各种维生素,多种矿质元素、氨基酸等有机物,营养价值极高。最著名的是小麦芽中含有的维生素E尤为丰富。具有美容养颜、延缓衰老、预防冠心病和高血压、炎症性皮肤病、脱发症、调整荷尔蒙、活化脑下垂体、改善血液循环、强化肝细胞膜、保护肺泡细胞、加速伤口的愈合等功效。国际知名品牌安利产品(纽崔莱)的维生素E就是从小麦芽中精制的。因此,小麦芽产品具有很好的清肠排毒、改变酸性体质、增强免疫力及抗衰老等作用。目前市场上除维生素E产品外,尚有易健牌小麦芽罐装饮料等。黑小麦的保健作用尤为明显,黑小麦中的蛋白质、氨基酸、以及钙、锰、铁、锌等元素显著高于普通小麦,种皮中富含花青素类物质,足见其食疗保健价值要远远高于普通小麦。
牛蒡为中国古老的药食两用蔬菜,明朝李时珍称其“剪苗淘为蔬,取根煮,曝为脯,云其益人”,《本草纲目》中详载其“通十二 经脉,除五脏恶气”;《名医别录》称其“久服轻身耐老”。中医认为有疏风散热、宣肺透疹、解毒利咽等功效。可用于风热感冒、咳嗽痰多、麻疹风疹、咽喉肿痛。研究表明,牛蒡有明显的降血糖、降血脂、降血压、补肾壮阳、润肠通便和抑制癌细胞滋生、扩散及移弃水中重金属的作用。牛蒡根含有人体必需的各种氨基酸,且含量较高,尤其是具有特殊药理作用的氨基酸含量高,如具有健脑作用的天门冬氨酸占总氨基酸的25%~28%,精氨酸占18%~20%,且含有Ca、Mg、Fe、 Mn、 Zn等人体必需的大量元素和微量元素;其多酚类物质具有抗癌、抗突变的作用,因而具有很高的营养价值和较广泛的药理活性,是非常理想的天然保健食品。中国《现代中药学大辞典》、《中药大辞典》等国家权威药典中把牛蒡的药理作用概括为三个方面:有促进生长作用、有抑制肿瘤生长的物质和有抗菌和抗真菌作用。2002年国家卫生部把牛蒡列入可用于保健食品的物品名单。牛蒡茎叶含挥发油、鞣质、粘液质、咖啡酸、绿原酸、异绿原酸等。牛蒡果实含牛蒡甙、脂肪油、甾醇、硫胺素、牛蒡酚等多种化学成分,其中脂肪油占25%~30%,碘值为138.83,可作工业用油。药理实验表明,牛蒡的纤维可以促进大肠蠕动,帮助排便,降低体内胆固醇,减少毒素、废物在体内积存,达到预防中风和防治胃癌、子宫癌的功效。西医认为它除了具有利尿、消积、祛痰止泄等药理作用外,还用于便秘、高血压、高胆固醇症的食疗。牛蒡中含有的低聚寡糖(以低聚果糖为主)是重要的功能性成分,有抑菌消炎、加速胃肠蠕动、改善肠道微生物菌群等诸多功效。目前市场上有专门从牛蒡提取的低聚寡糖、木脂素、挥发油、多酚等产品用于医药及保健品行业。
紫薯中含有丰富的蛋白质,18种易被人体消化和吸收的氨基酸,维生素C、B、A等8种维生素和磷、铁等10多种天然矿物质元素。其中铁和硒含量丰富。而硒和铁是人体抗疲劳、抗衰老、补血的必要元素,特别是硒被称为“抗癌大王”,易被人体吸收,可留在血清中,修补心肌,增强机体免疫力,清除体内自由基,抑制癌细胞中DNA的合成和癌细胞的分裂与生长,预防胃癌、肝癌等癌病的发生。紫薯富含纤维素,可增加粪便体积,促进肠胃蠕动,清理肠腔内滞留的粘液、积气和腐败物,排出粪便中的有毒物质和致癌物质,保持大便畅通,改善消化道环境,防止胃肠道疾病的发生。紫薯含有大量药用价值高的花青素,法国科学家马斯魁勒博士发现花青素是天然强效自由基清除剂。花青素对100多种疾病有预防和治疗作用,被誉为继水、蛋白质、脂肪、碳水化合物、维生素、矿物质之后的第七大必需营养素。花青素是目前发现的防治疾病、维护人类健康最直接、最有效、最安全的自由基清除剂,其清除自由基的能力是维生素C的20倍、维生素E的50倍。花青素具有小分子结构,是惟一能透过血脑屏障清除自由基保护大脑细胞的物质,同时能减少抗生素给人体带来的危害。临床研究证明,花青素具有抗氧化作用,抗突变作用,以及具有保肝和减少心血管疾病的作用。
申请公布号CN 101692886 A(申请号200910014891.5)的中国专利文献公开了一种多微保健黑小麦麦芽粉的生产方法。目前市场上尚缺乏功能全面、适于长时间服用的保健品。
发明内容
针对现有技术的不足,本发明提供一种利用富硒黑小麦芽为主要原料,辅以牛蒡、紫薯和黄芪的片剂或粉剂的制备方法。
本发明的技术方案是:
降压护心复合营养剂,主要由下列原料制备而成,均为重量份:富硒黑麦芽50-70;牛蒡30-40;紫薯10-20;黄芪10-15(优选的,黄芪11.5-14.5)。
所述的降压护心复合营养剂,优选的方案是,主要由下列原料制备而成,均为重量份:富硒黑麦芽50-60;牛蒡35-40;紫薯15-20;黄芪12-14。
所述的降压护心复合营养剂,优选的方案是,主要由下列原料制备而成,均为重量份:富硒黑麦芽60-70;牛蒡30-35;紫薯10-15;黄芪13-14。
所述的降压护心复合营养剂,优选的方案是,主要由下列原料制备而成,均为重量份:富硒黑麦芽60;牛蒡35;紫薯15;黄芪13.5。
所述的降压护心复合营养剂,优选的方案是,所用富硒黑麦芽、牛蒡和紫薯均为新鲜产品。
所述的降压护心复合营养剂的制备方法,是将富硒黑麦芽、牛蒡、紫薯和黄芪置于水中打浆,然后低温减压干燥后破壁粉碎,使用压片机制成片剂,或者分装成袋,制成粉剂。
本发明的优良技术效果体现在:
1、最大程度地保存了产品中的各种有效成分;
2、通过破壁技术,能够保证最大限度地吸收与利用有效成分;
3、本品营养功能、预防保健功能以及治疗功能较为全面;
4、本品因含有大量淀粉,因此无需单独添加赋形剂。
具体实施方式
下面结合实施例和实验例详细说明本发明的技术方案,但保护范围不被此限制。
本发明所用富硒黑麦芽的制备方法可以参照发明专利“一种多微保健黑小麦麦芽粉的生产方法(专利申请号为200910014891.5)”描述的方法制备。牛蒡和紫薯为市售菜用产品。
实施例1:降压护心复合营养剂,由下列原料制备而成,均为重量份(每份100g):富硒黑麦芽50;牛蒡30;紫薯10;黄芪10。
实施例2:降压护心复合营养剂,由下列原料制备而成,均为重量份(每份20g):富硒黑麦芽70;牛蒡40;紫薯20;黄芪15。
实施例3:降压护心复合营养剂,由下列原料制备而成,均为重量份(每份50g):富硒黑麦芽50;牛蒡35;紫薯15;黄芪12。
实施例4:降压护心复合营养剂,由下列原料制备而成,均为重量份(每份60g):富硒黑麦芽70;牛蒡35;紫薯15;黄芪14。
实施例5:降压护心复合营养剂,由下列原料制备而成,均为重量份(每份120g):富硒黑麦芽60;牛蒡35;紫薯15;黄芪13.5。所用富硒黑麦芽、牛蒡和紫薯均为新鲜产品。
实验列1 实施例5所得降压护心复合营养剂的功效实验。
随机选择50名高血压患者,平均年龄50.2岁,连续饮用本品(实施例5)一个月,每天早、中、晚饭前空腹服用本品各3片,或服用粉剂各1.5克。分别在服用本品前体检,在服用一个月后以及在停止服用一个月后再次体检,检测指标的平均值见表1。对高血压的影响:试验组在连续服用一个月后高压及低压都恢复到正常水平,说明本品起到了降压的作用。
由表1可以看出,在连续服用一个月后,参试患者的高压为125.6,低压为88.0,恢复到正常水平;结束一个月后的高压为130.8,低压为89.2,虽然略有升高,但是也在正常范围内,说明本品起到了降压的作用。
试验例2 实施例5所得降压护心复合营养剂的功效验证。
随机筛选100例有心肌缺血症状的患者,其中女性72例,男性48例,年龄最大的71岁,最小年龄45岁,平均年龄54.2岁。实验组饮用实施例5所得产品(连续饮用本品一个月,每天上午十点与下午三点左右分别饮用本品各5克),对照组服用其它药品(美托洛尔、利多卡因、去甲肾上腺素等常规药品)。判定标准:有效:30天为一个疗程,心电图示慢性冠状动脉供血改善,不适症状减轻或部分消失,精力及体力增强;无效:饮用一个疗程,不适症状无变化。效果:有效97例(97%),无效3例(3%),总有效率97%。效果明显优于对照组。饮用一个疗程,自感精神状态好转的占98%,心电图示冠状动脉供血改善94%;对照组仅为72%和73%。
Claims (6)
1.降压护心复合营养剂,其特征是,由下列原料制备而成,均为重量份:富硒黑麦芽50-70;牛蒡30-40;紫薯10-20;黄芪11.5-14.5。
2.根据权利要求1所述的降压护心复合营养剂,其特征是,各原料为:富硒黑麦芽50-60;牛蒡35-40;紫薯15-20;黄芪12-14。
3.根据权利要求1所述的降压护心复合营养剂,其特征是,各原料为:富硒黑麦芽60-70;牛蒡30-35;紫薯10-15;黄芪13-14。
4.根据权利要求1所述的降压护心复合营养剂,其特征是,各原料为:富硒黑麦芽60;牛蒡35;紫薯15;黄芪13.5。
5.根据权利要求1-4任一所述的降压护心复合营养剂,其特征是,所用富硒黑麦芽、牛蒡和紫薯均为新鲜产品。
6.根据权利要求1-4任一所述的降压护心复合营养剂的制备方法,其特征是,将富硒黑麦芽、牛蒡、紫薯和黄芪置于水中打浆,然后低温减压干燥后破壁粉碎,使用压片机制成片剂,或者分装成袋,制成粉剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101459307A CN102657333B (zh) | 2012-05-13 | 2012-05-13 | 降压护心复合营养剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101459307A CN102657333B (zh) | 2012-05-13 | 2012-05-13 | 降压护心复合营养剂及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102657333A CN102657333A (zh) | 2012-09-12 |
| CN102657333B true CN102657333B (zh) | 2013-04-10 |
Family
ID=46767018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101459307A Expired - Fee Related CN102657333B (zh) | 2012-05-13 | 2012-05-13 | 降压护心复合营养剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102657333B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104026517A (zh) * | 2014-06-26 | 2014-09-10 | 顾瑞芳 | 一种黄芪紫薯滋补品 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100566604C (zh) * | 2006-05-23 | 2009-12-09 | 沈彩奎 | 一种营养保健饮料及其制备方法 |
| CN102382751A (zh) * | 2010-08-31 | 2012-03-21 | 王军 | 一种紫薯牛蒡保健醋 |
-
2012
- 2012-05-13 CN CN2012101459307A patent/CN102657333B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102657333A (zh) | 2012-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3530277A1 (en) | Chinese medicine healthcare preparations for slimming and weight loss | |
| KR101646156B1 (ko) | 숙변 제거 효능이 있는 장 기능 개선 발효식품 및 그 제조방법 | |
| CN102640829B (zh) | 具有改善心肌缺血功能的茶膏及其制备方法 | |
| CN102697035A (zh) | 虫草褔寿丹 | |
| CN103263012B (zh) | 一种药食同源的保健食品及其制备方法 | |
| CN108618126A (zh) | 一种中药复方减肥特殊膳食食品及其制备方法 | |
| KR101883154B1 (ko) | 흰찰쌀보리를 이용한 당뇨예방에 도움을 주는 발효식품 제조방법 및 그에 의해 제조된 발효식품 | |
| CN103156108A (zh) | 一种防治糖尿病高血压病症的强化食品 | |
| CN106858215A (zh) | 一种百香果复合饮料 | |
| KR101826737B1 (ko) | 생약재 추출물을 유효성분으로 하는 근육틱 및 우울증 개선용 조성물 및 그의 제조방법 | |
| CN103181561B (zh) | 一种具有秋季养生保健作用的保健食品及其制备方法 | |
| CN105249440A (zh) | 一种阿胶糕 | |
| CN111387345A (zh) | 一种复合多糖组合物及其制备方法 | |
| CN102657333B (zh) | 降压护心复合营养剂及其制备方法 | |
| CN104206581B (zh) | 一种莞香花茶饮料及其制作工艺 | |
| CN102640893B (zh) | 一种黑麦芽全草复合营养剂及其制备方法 | |
| CN104206582A (zh) | 一种莞香叶茶饮料及其制作工艺 | |
| CN107259530A (zh) | 一种用于安神、改善睡眠的百香果配方食品 | |
| CN101828703B (zh) | 一种增强机体免疫力并能改善睡眠质量的产品及制备方法 | |
| CN101869329B (zh) | 延年益寿防癌保健饮料 | |
| CN104886681A (zh) | 高血糖富硒药食纳米元素饮料 | |
| CN104173745A (zh) | 一种滋补健身的蒙药 | |
| KR20200057243A (ko) | 집중력 및 기억력 향상에 효과적인 학습 능력 증진용 건강 기능성 식품 조성물의 제조방법 | |
| CN101584475B (zh) | 抽烟者营养保健天然生物组合物 | |
| CN108433051A (zh) | 一种安神养胃助消化的天然型功能食品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130410 Termination date: 20140513 |
